This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ellwein, L. B. Articles by Farrow, G. M. Search for Related Content PubMed PubMed Citation Articles by Ellwein, L. B. Articles by Farrow, G. M. Social Bookmarking                         What's this?

Urinary Cytology Screening

The Decision facing the Asymptomatic Patient

George M. Farrow, MD

Voided-urine cytology as a screen for the early detection of urinary bladder cancer is analyzed to determine its potential in an asymptomatic population. Previous cost-effectiveness as sessments predict that screening will extend life-span at a cost-per-detected-case that is comparable to those of other cancer screening efforts. The focus here is on investigating screening from the perspective of the individual contemplating the screening decision. The analysis is based on a computerized model of bladder cancer which integrates a Markov representation of the induction and progression of the disease with algorithms representing diagnostic and therapeutic intervention strategies, intervention effectiveness, and cost. It is shown that the utilities, as well as the probabilities, of true-positive, false-positive, and false- negative screening outcomes are affected by the particular testing regimen employed and the age at which screening takes place. Screening at age 55 or age 65 was analyzed for individuals of normal risk. Analyses predict that the predisposition of cytology screening to identify the high-grade, aggressive form of the disease will result in gains in life expectancy of more than three years for the asymptomatic true-positive case. Results support the decision to screen, and by requiring a repeatedly positive test result, the probability of a false-positive outcome will not exceed that of a true-positive outcome at age 65. Except for the risk of a false-positive outcome, cytology screening compares favorably with what could theoretically be obtained if a 100% accurate screening test were available. Key words: cytology screening; decision analysis; disease modeling; bladder cancer. (Med Decis Making 8:110-119,1988)

Medical Decision Making, Vol. 8, No. 2, 110-119 (1988)
DOI: 10.1177/0272989X8800800207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Benbassat, G. Zajicek, G. J. Van Oortmarssen, I. Ben-Dov, and M. H. Eckman Inaccuracies in Estimates of Life Expectancies of Patients with Bronchial Cancer in Clinical Decision Making Med Decis Making, August 1, 1993; 13(3): 237 - 244. [Abstract] [PDF]

				G. B. Hazen Stochastic Trees: A New Technique for Temporal Medical Decision Modeling Med Decis Making, August 1, 1992; 12(3): 163 - 178. [Abstract] [PDF]

				A. J. Munro and P. R. Warde The Use of a Markov Process to Simulate and Assess Follow-up Policies for Patients with Malignant Disease: Surveillance for Stage I Nonseminomatous Tumors of the Testis Med Decis Making, June 1, 1991; 11(2): 131 - 139. [Abstract] [PDF]